Recent investigations into the etiology and pathogenesis of Alzheimer's disease (AD) in the past few years have expanded to include previously unexplored and/or disconnected aspects of AD and related conditions at both the cellular and systemic levels of organization. These include how AD-associated abnormalities affect the cell cycle and neuronal differentiation state and how they recruit signal transduction, membrane trafficking and protein transcytosis mechanisms to produce a neurotoxic syndrome capable of spreading itself throughout the brain. The recent expansion of AD research into intercellular and new aspects of cellular degenerative mechanisms is causing a systemic re-evaluation of AD pathogenesis, including the roles played by well-studied elements, such as the generation of Aβ and tau protein aggregates. It is also changing our view of neurodegenerative diseases as a whole. Here we propose a conceptual framework to account for some of the emerging aspects of the role of tau in AD pathogenesis.
Introduction / historical perspective
In the quarter century that has passed since the proteins that constitute the defining For most of the 100+ years since the publication of the case report of "dementia praecox" by Alois Alzheimer in 1907 [1] , AD was considered to be a rare familial condition (FAD) featuring an autosomal dominant inheritance pattern, a midlife onset followed by rapid cognitive decline and a characteristic neuropathological proliferation of cerebral SP and NFT. During this period AD was studied and its lesions characterized by investigators using traditional clinical [2, 3] genetic [4] [5] [6] [7] neurohistochemical [8, 9] and ultrastructural [10] approaches, with almost nothing being known about its etiology or pathogenesis beyond some indications that AD was associated with damage to cholinergic pathways [11, 12] . It was not until the mid 1980s that it became clear that most cases of senile dementia (i.e. "senility") were neurologically indistinguishable from AD, prompting a detailed molecular characterization of the main component proteins of SP (β-amyloid or Aβ) [13] and NFT (tau) [14] [15] [16] [17] [18] [19] , which in turn quickly focused attention on the genetics, biogenesis, function and potential neurotoxicity of these agents. This was particularly true of Aβ and its generation via the proteolytic cleavage of its parent protein (amyloid precursor protein or APP) [20] . By 1991, the demonstration of a direct link between mutations in APP and the FAD syndrome in several families [21] [22] [23] 
The amyloid cascade hypothesis
The amyloid cascade hypothesis (first put forward by Hardy, Selkoe, Bayreuther and colleagues in the early 1990s) was the first modern attempt to define the etiology of FAD in specific terms [24, 25] . It was based on several landmark studies of families with autosomally dominant AD traceable to chromosome 21 . It accounted for the increased amount and/or toxicity generated by the so-called "framing" mutations in APP [21, 23] , and was consistent with the long known link between Down's syndrome (trisomy 21) and AD [4] . By the mid 1990s, the original genetic basis for the amyloid cascade hypothesis (i.e. that the cleavage of APP by β and γ secretases (at the N-and C-termini of Aβ, respectively was the cause of at least some forms of familial AD).
A central role for Aβ generation in AD was
consistent with early acetylcholine pathway associated damage [26] , known genetic and environmental risk factors, including the ApoE4 allele [27, 28] and head trauma [29, 30] .
Furthermore, the toxicity of Aβ had also been largely supported by results from both cell culture [31, 32] and in a transgenic mouse model [33] . The subsequent identification of presenilins 1 and 2 (the most common source of FAD mutations overall) as an element in the γ secretase complex [34] confirmed earlier results and established the value and importance of the amyloid cascade hypothesis to understanding AD. This hypothesis was the basis for the generation of the first AD mouse model (the so-called "Athena mouse"), in which Aβ was strongly overexpressed in the CNS, resulting in the development of significant plaque pathology closely resembling that seen in AD and Down's Syndrome brain [33] .
The numerous CNS plaques found in Athena mice were accompanied by changes in tau phosphorylation resembling early "pre-tangle" neurofibrillary pathology in humans; these mice also replicated some of the earliest cognitive deficiencies typically seen with human AD. While these findings appeared to be a strong validation of the Amyloid Cascade Hypothesis to many at the time, the failure of other AD features (e.g. widespread neuron loss, the development of NFT) to develop in these mice was later seen to be evidence that factors in addition to APP misprocessing and plaque formation are required to explain the full spectrum of AD-related changes.
Tau -the amyloid cascade hypothesis is incomplete
The focus on Aβ pathobiology that was the prevailing state of affairs through the mid1990s was by no means absolute; much effort at this time was also directed at the characterization of NFT, which by this time had been shown to be somatodendritically localized, hyperphosphorylated, aggregated forms of tau -a cytoskeletal protein hitherto largely associated with axonal microtubules in the CNS [14, 15, [35] [36] [37] [38] [39] . Phosphorylationregulated binding of tau to microtubules [40] was known to occur via the microtubulebinding region (MTBR), a set 3 or 4 conserved tandem repeat motifs in the tau C-terminal domain [41, 42] . In AD, phosphorylated tau aggregates consisting primarily of the MTBR were found to make up "paired helical filaments" (PHF), the key structural component of NFT [43] [44] [45] . The best evidence for a central role of tau in AD pathogenesis was the result of a series of studies by Heiko and Eva Braak and colleagues that demonstrated a progressive sequence of neurofibrillary pathology illustrating the spread of NFT in the CNS [18] . This work established a timeline for NFT lesion progression through the CNS in AD that was tightly correlated to the initial presentation and progression of clinical symptoms [46, 47] . This "Braak pattern" of NFT development begins in the limbic cortex of the temporal lobe and progresses to association (polymodal) areas of the neocortex, leaving primary sensory and motor areas unaffected until end stage disease has set in. Despite the tight correlation between tau pathology (i.e. NFT distribution) and clinical presentation of AD, interest in the role played by tau in AD pathogenesis was initially limited by 1) the failure to identify mutations in the TAU gene that could be directly linked to FAD and 2) the inability of tau overexpression to cause neurotoxicity in cell culture models [48] .
It was not until a) the identification of both exonic and intronic tau mutations as being responsible for the familial forms of a subset of non-AD neurodegenerative syndromes [49] [50] [51] and b) the successful production of cellular [52] and transgenic [53- [65] [66] [67] [68] [69] . However, the ability of intronic mutations to induce dominant familial tauopathy syndromes by creating an imbalance between three and four-repeat tau isoforms [70] [71] [72] also demonstrated that tau toxicity is dependent on an extremely subtle interplay between the parameters associated with MT:tau binding, tau:tau binding, and tau hyperphosphorylation.
Most evidence before 2002 suggested that tau toxicity was exclusively mediated by the tau C-terminal domain and in particular the MTBR, since this region comprises the "core" of PHF and thus is essential for NFT formation [73, 74] . Still, a significant interaction between the tau N-terminal projection domain and the plasma membrane and in particular src family kinases had also been identified [75] and shown to be associated to be neurofibrillary pathology in AD [76] [77] [78] [79] . Such results served as a reminder that MTBR-mediated tau aggregation, however important, could not be considered in isolation from other cis-acting factors that must also be involved in tau-associated neuropathogenesis. [80] [81] [82] [83] . Other very early (pre-fibrillar) disease-associated changes include lysosomal hypertrophy [84, 85] as well as the colocalization of a variety of development-associated regulatory proteins, including GSK3β, CDK5, MARK kinases, CRMP2, and GAP43 [86] [87] [88] [89] [90] . Additional abnormalities associated with pre-fibrillar neurons include evidence for the reactivation of developmental programs normally associated with tau, especially those associated with axonal identity [91, 92] , and other aspects of axonogenesis [93] [94] [95] [96] . Moreover, it emerged that the primary genetic and environmental risk factors for developing LOAD were (respectively) the ApoE4 allele [27] , and severe or repeated head trauma [97] [98] [99] . The latter was also known to cause non AD neurofibrillary conditions such as dementia pugilistica [97, 98] , which later became associated with other contact sports and battlefield injuries as chronic traumatic encephalopathy (CTE) [99] . Finally, the ability of wild type (WT) tau species to induce degeneration in both cellular and murine transgenic in situ [52, 53] , but not in cell culture lines had not (and has not since) been satisfactorily explained. This ability appears to imply that tau toxicity is dependent on the full differentiation of certain neuronal characteristics (i.e. fully differentiated synapses and axons and dendrites) that can only be found in situ [48, 52] circumstances and is thus very likely to do so in AD as well. This second point was established by demonstrations both in situ [55] and in primary neuronal culture [100, 101] that the presence of human tau is a necessary and sufficient condition for toxicity induced by Aβ. While tau overexpression in an in situ cellular model had caused clear tau-specific neurodegeneration [52] , murine transgenic models that expressed WT human tau at physiological levels caused only minimal somatic tau accumulation with no apparent toxicity [102, 103] and mild overexpression (5x) of WT tau produced some tau aggregates in elderly mice [53] , which left open the possibility (at least for for some) that tau-induced toxicity might be of limited relevance to human disease. However, Götz and coworkers showed that cerebral microinjection into WT tau-expressing mice readily induced NFT formation in the vicinity of the injection site [55] . This suggested that Aβ might be playing a role comparable to that of tauopathy mutations in the exacerbation of toxicity-associated characteristics of tau protein resulting in NFT formation. This was consistent with earlier findings that Aβ induced tau phosphorylation and MT loss in cell culture [31] in a manner similar to that of tauopathy mutations [51, 61, 104, 105 ]. An essential role for tau in mediating Aβ toxicity was directly demonstrated in an experiment by Rapoport and coworkers, who used primary cortical neurons taken from a tau KO mouse [106] to show that Aβ toxicity was completely dependent on tau expression Since tau is inherently prone to fibrillization [116] and since the tau proteins comprising PHF and NFT appear to evolve over time from full length to truncated species containing mainly the MTBR domain [117] , it seems very likely that Aβ drives NFT formation via a truncation mediated mechanism. Studies of tau aggregate development transgenic mice [75] and non-receptor tyrosine kinases such as fyn and src [76] are examples of such functions.
Hints of other links to Alzheimer's disease mechanisms
In general, non-MT-associated tau functions can be characterized as involving an alternative association of either MTBR region [94, 121, 122] or N-terminal domains of tau with subcortical actin [75] , actin-associated proteins such as dynactin [123] [124] [125] and membrane associated proteins involved in signal transduction such as fyn and src [126] . Additional non-
MT interactions of tau occur with chaperone
proteins such as Pin1 [127] ChIP [128] and HSPc70 [129] . All of these interactions now appear to play some role in tau pathobiology, Where in the cell do tangles form, and do tangles matter?
Although it now seems clear that tau is abnormally processed in the adult CNS when it ceases to bind to MT in the "classical" manner, It has generally been assumed that the formation of tau aggregates occurs directly via oligomerization to granular aggregates or "pre-tangles" in the cytosol [130, [146] [147] [148] although this process has not been extensively characterized in cellular tauopathy models.
However, the links between misprocessed tau and src family kinases, lipid rafts and membrane trafficking [126, 145] by an excess of non-MT-associated tau [175, [180] [181] [182] . Proteomic analysis of a neuroblastoma exosomal-associated proteome consistent with this is presented in Figure 1 .
Interestingly, recent reports of vesiclemediated tau transport [178] , vesicle associated tau secretion [166, 179] These changes appear to be correlated with age-related sex hormone level decreases, which could exacerbate early synaptic damage associated with Aβ accumulation in AD [229] .
Similarly, high levels of synaptic and dendritic plasticity may impart vulnerability of certain cortical brain regions to tauopathy, at least in AD, as highly plastic regions such as the hippocampus and neocortical "association" areas appears to be subject to NFT formation early in AD [18, 140] while the relatively "hard wired" primary sensory and motor cortices rarely exhibit neurofibrillary degeneration until very late stages [80] . Interestingly, alterations in spine structure and other plasticity-associated changes caused by tau misprocessing [236, 237] may well involve the small amount of tau that is normally localized to the postsynaptic region [52, 143, 179, 190, 191] .
More recently, studies of tau secretion have also been pursued in cell culture as well [166, 178, 209, 239] . It now appears that tau can be secreted from neurons in situ by multiple cellular pathways [179, 192] and that the presence or absence of the MTBR is an important determinant of both the secretion Figure 1 . Proteomic analysis of exosomes in neuroblastoma cells overexpressing 4R0N tau suggests links between tau secretion, AD, autophagy abnormalities and APP misprocessing. A proteome of 669 proteins from exosome samples taken from M1C neuroblastoma cells was identified by mass spectometic analysis as described [166] . Prescreening was done using a large panel of 616 AD associated proteins [187] and 1968 general neurodevelopmental proteins based on String interactors [188] with axonogenesis and morphogenesis-associated proteins. These included tissue morphogen pathways (wnt, fzd, Ssh, Hox, Notch), growh factor pathways (EGF, FGF, NGF, PDGF, BDGF) and axonal guidance pathways (semaphorins, netrins, ephrins and slit). Panel A: summarizes the results of GO based analysis of this proteome using the online String 9.05 program [187] . Proteins present in this dataset and absent from a control neuroblastoma exosomal dataset (638 proteins)
[188] produced a set of 142 proteins unique to the exosomal proteome of M1C cells induced to overexpress 4R0N tau [166] . The Venn diagram (A, bottom) summarizes the GO term characterization of this dataset using much more restrictively defined protein sets. Proteins associated with AD (hsa05010), mitochondria (oxidative phosphorylation -hsa 00190) and axonogenesis (hsa04360), showed highly significant recruitment into this proteome. Panel B: Connectivity analysis of the 142 protein dataset described in A. The strength and degree of relatedness between proteins (identified by gene name) is given by the length and thickness of the blue lines. Note that the AD signal recruited by tau overexpression recruits mitochondrial proteins normally not present in exosomes (red/green hatched proteins) suggesting the diversion of autophagosome contents into exosomes (exophagy) [181] . An entirely separate subset of AD-associated proteins (yellow/ red hatch) co-localized significantly with proteins involved in axonogenesis. Panel C: Interestingly, tau overexpression results in the significant enrichment of APP-associated proteins (the top 500 APP interactors identified by String) relative to the control neuroblastoma exosomal proteome (p < 0.01, Fisher's Exact test). This was accompanied by a significant increase in the proportion of AD associated (red) and synapse associated (blue) proteins, suggesting that abnormal tau localization to the membrane caused by overexpression [145, 179, 190, 191] potentiates AD-associate misprocessing of APP, possibly in a synapse-associated context.
mechanism [178] and the resulting pattern of extracellular accumulation and transport [193] . In the lamprey model, tau secretion occurs before the onset of degenerative cellular changes [192, 193] , suggesting that extracellular tau in AD brain and CSF is very likely due to secretion rather than passive release from dead or dying neurons as has been commonly been assumed [166, 194] .
The propensity of tau to oligomerize may well be a factor in favoring its secretion, since the presence of tauopathy mutations also favor secretion [183, 192, 193] and uptake [195] .
Dimeric and trimeric CSF species have also been observed in early stage AD patients [166] , suggesting that oligomerization may occur with secretion. However, the role played by oligomerization in tau secretion (and thus in lesion spreading) is still unclear, since treatment of tau-overexpressing neurons with antiaggregating drugs greatly increases the efficacy of secretion in situ [191, 196] , but oligomerized tau appears to be preferentially taken up from the medium in some cell culture models [195, 208] . Tau now appears to be secreted at least in part via the exosome pathway [166] as are other aggregation-prone proteins associated with neurodegenerative disease such as β-amyloid [197] , α-synuclein [198] and prion protein [199] . Ongoing proteomic analysis of exosomal proteins recruited by tau into this secretion pathway in our laboratory suggests that tau misprocessing could drive secretion via a mechanism involving elements of synaptic function, APP misprocessing, and the diversion of autophagal lysosome contents into the exosomal secretion pathway (Figure 1 ).
Is tau a prion?
A major recent focus of interest have been the question of whether tau toxicity is propagated interneuronally via a prion-like mechanism involving a "templated" induction of specific toxic conformations in normal tau proteins in recipient neurons, and thus spreading toxicity and neurofibrillary lesions throughout the brain. While this mechanism has hitherto been considered unique to prion diseases [199] [200] [201] , the Braak sequence of lesion progression in AD [18] and similar sequences for other tauopathies [18, [202] [203] [204] [205] [206] have long hinted at trans-synaptic mechanisms of lesion spreading, and very recently evidence has accumulated in both cellular [194, [207] [208] [209] and transgenic [183] [184] [185] 210, 211] tauopathy models that supports the existence of tau:tau interactions that result in the transformation of normal tau isoforms into toxic species.
Moreover, tau lesion spreading patterns within the brains of mouse tauopathy models [184, 185, 211, 239] and the existence of common molecular characteristics between tau, the prion protein and other aggregation prone proteins including Aβ [175, 200, 201] suggests that this mechanism could well be operative in human tauopathy [183, 184, 213] .
There are also a number of parallels between transsynaptic lesion spreading patterns in tauopathy with the protein-mediated interneuronal transfer that is characteristic of prion-based disorders such as transmissible spongiform encephalopathies (e.g. CreutzfeldJakob disease, fatal familial insomnia), which certainly suggests that it could be relevant to human neurodegenerative disease [240] .
However, it is very difficult to show that such a mechanism can (and more importantly [108, 109, 138, 139, 213, 214] .
This type of mechanism would be consistent with reports that tau binds to NMDA and muscarinic acetylcholine receptors, causing changes in intracellular calcium levels [109, 138, 139, 195, 214] . It is worth noting in this context that both C and N-terminal tau fragments could possibly mediate neurofibrillary lesion spread in tauopathies via templated misfolding, oligomer-associated secretion, and/or calcium dysregulation mechanisms, respectively [213] . Figure 2 . Hypothesized sequence of cellular events in tauopathy. We propose that tau misprocessing mediates Aβ initiated changes (AD) or directly induces (non-AD tauopathy) a cascade of toxic changes resulting in neurodegeneration via a hypothetical sequence of events as described. This sequence would account for and integrate Aβ synaptotoxicity, cell cycle re-entry mechanisms and aggregate formation in the context of both known predisposing genetic and environmental factors in LOAD and the unique distribution of tau in mature cortical neurons, where it resides primarily in the axon but also in perisynaptic zones within dendrites. Panel A: A-beta based abnormalities serve as the primary initiating factor of tau toxicity in familial AD (left). Age and genetic background-related factors (ApoE4 allele, tau haplotype) in combination with environmental predisposing factors (P) (traumatic head injury) precipitate the onset of LOAD. The initiating event (1a) involves APP misprocessing to A-beta in synapses and endosomes, occurring in the context of tau normally present in the postsynaptic density. Both of these are associated with cell cycle re-entry (1b), which sets off de-differentiation-related changes (2a) that damage that preferentially damage terminally differentiated neuronal structures such as axons, dendrites and synapses and compromise the localization of tau to the axon (2b). The failure of tau localization mechanisms that normally route most tau proteins to the axon [214, 215] prompt the reactivation of developmental programs such as the aberrant outgrowth of axon-like processes (2c). Furthermore, abnormal accumulation of phosphorylated, non-MT-associated tau in the soma results in its abnormal transport into dendrites [179] , where it interacts with somatodendritic signaling pathways (3). This eventually results in amplified tau-Aβ toxic interactions (3a) and other toxicity associated events (3b) such as tau secretion and tau aggregate formation. This sequence of events is attended by the progressive accumulation of toxic tau cleavage fragments, oligomers and (possibly) prion-like misfolded tau species. Panel B: A detailed view of the cellular consequences of somatodendritic tau accumulation described in A. Somatodendritic tau misprocessing leading to toxicity, aggregate formation and interneuronal lesion propagation in tauopathy. Non-MT-associated tau becomes phosphorylated at multiples sites and vulnerable to proteolytic cleavage which generates toxic C-terminal (MTBR+) and N terminal (MTBR-) fragments. These are transferred trans-synaptically secreted to the extracellular space, the CSF and the ventricular and meningeal surfaces of the brain, where they are associated with and may mediate the interneuronal spreading of tau pathology [192, 206] .
A unifying hypothesis of FAD and LOAD cytopathogenesis centered on tau
present a hypothetical sequence of events (labeled 1-3 in Figure 2a ) that integrates APP misprocessing, tau abnormalities, and ancillary factors in AD pathogenesis, together with mechanisms by which LOAD risk factors (P) could exacerbate this process. A summary of this hypothesis is given in Figure 2 .
Predisposing risk factors to the development of LOAD
The repeated head trauma seen in contact sports and military action [99, 221] . Axonal damage was among the first identified features of LOAD pathology [34] and subsequent studies using axotomy models established a link between the loss of overall neuronal polarity and perisomatic axonal injury [222] [223] [224] [225] . We propose that an interplay between predisposing factors such as axon injury or reduced mitochondrial function amplify axonal changes due to tau misprocessing, neuronal dedifferentiation and Aβ generation [226] [227] [228] [229] [230] . These factors may then initiate a cascade of events leading to plaque/tangle generation and neurodegeneration. These include the appearance of apoptotic and mitotic markers in "pre-tangle" neurons [155] [156] [157] and the activation of developmentassociated signal transduction pathways resulting in aberrant cellular changes normally associated with development, such as neuropil thread formation [17, 19, 241, 242] . Tau kinases such as CDK5, GSK3β and Mark1 normally play critical roles in cell cycle control, establishment of neuronal polarity and axonal outgrowth [243] [244] [245] [246] , so their roles in tau toxicity may therefore be due to aberrant activation of these same functions during the course of AD pathogenesis [147, [247] [248] [249] 3b Dendritic tau accumulation leads to tau secretion via multiple mechanisms
Amplified toxic interaction between Aβ and tau (directly [261] or via intermediates [262, 263] very likely occurs in the endosome in the context of Aβ generation from APP and oligomer formation [175] and the exosomemediated secretion of membrane proteins [197] and thus may account for the seeding of cellular tau aggregates as well as mediating tau lesion spread [163] especially as association of tau with cellular membranes and membrane elements favors tau oligomerization [171] [172] [173] . Both secretion and trans-synaptic tau movement have been associated with the presence of tauopathy mutations [183, 192] , suggesting that either the oligomerization or enhanced proteolytic cleavage of tau associated with these mutations result in the formation of more toxic N-and C-terminal fragments, which then may be secreted, possibly via multiple pathways [193] . 
Conclusion
For the past few years, the consensus view of 
